It added that broadening access to clinical trials was essential to improve knowledge of the best treatments for cancers.

BBC: Young cancer deaths 'halved in last 30 years'

This is unlikely to surprise some investors, but a new study has determined that advanced knowledge of Phase III clinical trials of new cancer meds and FDA decisions may affect the publicly traded shares prices of drugmakers.

FORBES: Why Pharma Stocks May Rise Before Trial Data Is Released